AstraZeneca’s lung cancer drug Tagrisso receives full approval in the EU
AstraZeneca announced that the European Commission (EC) has granted full marketing authorisation for Tagrisso (osimertinib) 40mg and 80mg once-daily tablets for the treatment of adult…
Read More...
Read More...